Skip to main content

Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience

Dear Editor,

Multiple myeloma (MM) is a disease characterized by the clonal expansion of malignant plasma cells in the marrow, leading to anemia, hypercalcemia, bone lesion, and renal dysfunction [1]. Immunoglobulin D (IgD) myeloma is a rare subtype of MM, accounting for approximately 1% to 2% of all MM patients [2]. It occurs at a young age, often accompanied with a high disease burden and short median survival (18–21 months) [3, 4]. Several studies have suggested that in patients with IgD subtype, the outcomes of those who have had undergone autologous stem cell transplantation (ASCT) were superior than those treated with chemotherapy alone [5, 6]. However, these have been debatable as other reports have displayed opposite results [7, 8].

In the last decade, novel agents such as proteasome inhibitor and immunomodulatory agents have been used to treat MM, which have resulted in a 50% improvement in the patients’ overall survival (OS: 44.8 vs. 29.9 months) [9]. However, given the rarity of IgD myeloma, studies on it remain rare. Knowledge about this subtype was mostly derived from few single-center case series. In China, there has been no report to fully elucidate on whether the results of survival outcomes for patients with IgD subtype from novel agents could be replicated in those with non-IgD subtypes. Here, we performed a retrospective analysis on 216 symptomatic MM patients, diagnosed from August 2006 to April 2018, at the Jinling Hospital (Nanjing, Jiangsu, China). The patient cohort comprised of 13 with IgD subtype and 203 with non-IgD subtypes. Three new drugs, bortezomib, thalidomide, and lenalidomide, were used as induction therapy choice, based on which we investigated their clinical manifestations, treatment responses, and outcomes. In this study cohort, 1 patient with IgD subtype and 11 with non-IgD subtypes underwent ASCT.

First, we compared the clinical features between the IgD and non-IgD subtypes (Table 1). The median age of onset for the IgD subtype was 52 years, which was younger than that of the non-IgD subtypes (60 years, P = 0.028). The rate of λ light chain was significantly higher in patients with the IgD subtype than in those with non-IgD subtypes (92.3% vs. 48.8%, P = 0.006). Moreover, as compared with non-IgD subtypes, patients with IgD subtype presented more often with significant renal dysfunction (creatinine > 2 mg/L, P < 0.001) and amyloid light-chain (AL) amyloidosis (P = 0.001) and had higher frequencies of critical clinical features such as International staging system (ISS)-III disease (P = 0.002), severe anemia (Hemoglobin < 90 g/L, P = 0.011), high β2 microglobulin (β2Μ) concentration (P = 0.001), and elevated lactate dehydrogenase (LDH > 250 U/L, P = 0.002). However, there were no significant differences in sex, platelet counts, bone lesion, hypercalcemia, urine protein, induction therapy, and extramedullary infiltration between IgD and non-IgD subtypes.

Table 1 Clinical characteristics and treatment of 216 patients with multiple myeloma

Based on the data from Table 2, we found that 30.8% (4/13) of patients with IgD subtype presented with significant abnormalities in serum-free light chain (sFLC) ratio (< 0.01 or > 100) at baseline, compared with 7.5% (13/173) for the non-IgD subtypes (P = 0.021). Moreover, about half of those (46.2%) with IgD subtype showed an obvious increase in sFLC ratio abnormalities when relapsed (P < 0.001).

Table 2 The sFLC concentrations and abnormal ratios of the investigated 186 patients

Of the 216 MM patients, 198 (91.7%) were subjected to cytogenetic abnormality testing (Table 3). 1q21 amplification was discovered in 9 patients with IgD subtype, which was higher than that in patients with non-IgD subtypes (75.0% vs. 40.3%, P = 0.018). The rate of t (14;16) was also significantly higher in patients with IgD subtype than those with the non-IgD subtypes (17.0% vs. 1.6%, P = 0.023). However, no significant differences in other cytogenetic abnormalities such as 13 deletions, t (4;14), t (11;14), p53 deletion, and hyperdiploid between the IgD and non-IgD subtypes were found.

Table 3 Abnormal cytogenetic characteristics in 198 case of MM patients

Second, we analyzed the treatment response between the IgD and non-IgD subtypes and have listed their detailed information regarding the treatment and survival of the patients with IgD subtype in Table 4. By the end of follow-up on August 31, 2018, 71 deaths were recorded of whom 9 cases (69.2%) were from patients having the IgD subtype. The overall response rate of the entire cohort was 93.5% (202/216). Response of induction therapy for the IgD subtype was similar to that of the non-IgD subtypes (P = 0.847, Table 1). However, the median duration of response in patients with IgD subtype was 10 months, which was significantly shorter than that of patients with non-IgD subtypes (23.6 months, P = 0.002) (Fig. 1a). The median follow-up of the 216 patients was 32.4 months (range 0.96–147 months). In patients with IgD subtype, the median progression-free survival (PFS) was 10.0 months and the median OS was 22.9 months, compared with 27.9 months (P = 0.003; Fig. 1b) and 81.7 months (P < 0.001; Fig. 1c) for patients bearing the non-IgD subtypes.

Table 4 Treatment and survival of the 13 patients with IgD subtype MM
Fig. 1

a Duration of response in patients with IgD subtype or non-IgD subtypes of multiple myeloma, b Kaplan–Meier progression-free survival curves of patients with IgD subtype or non-IgD subtypes of multiple myeloma, c Kaplan–Meier overall survival curves of patients with IgD subtype or non-IgD subtypes of multiple myeloma

Lastly, we analyzed the other risk factors that might have affected the prognoses of the investigated MM patients (Additional file 1: Table S1). Univariate analyses showed that, besides the IgD subtype, patients with high β2M level, elevated LDH level, having extramedullary infiltration, ISS stage III, 13q deletion, 1q21 amplification, IGH rearrangement, and abnormal sFLC ratio had shorter OS compared with their counterparts (Additional file 2: Figure S1). Multivariate analyses showed that IgD subtype was an independent adverse factor for both PFS (P = 0.009) and OS (P = 0.001) (Table 5).

Table 5 Multivariate analysis for PFS and OS of 216 patients with multiple myeloma

The synthesis rate of IgD is very low in patients bearing the IgD subtype, which often leads to missed diagnosis [2]. Among the 216 MM patients, 13 had IgD subtype (6%). This proportion was similar to another report in China (5.4%) [8] but was slightly higher than that observed in western countries (1%–2%) [2]. Nevertheless, the proportion of IgD subtype may still be underestimated, therefore, identifying and understanding this disease is extremely essential.

It has been reported that the IgD subtype of MM occurred more often in young patients, with a median age of 52 to 60 years. Moreover, it was found to be associated with higher β2M, extramedullary involvement, secondary systemic amyloidosis, a λ light chain bias (IgD myeloma is characterized by the presence of a predominance of λ over K light chain type), renal failure, and short survival [3]. The clinical characteristics of our patients were similar to the results of the above-mentioned studies.

In addition, we interestingly found that patients with the IgD subtype demonstrated significant sFLC ratio abnormalities at baseline and during disease relapse, especially in the 46.2% of patients with disease relapse. This finding may be conducive to assess the disease progression and to identify early relapse for timely intervention. Moreover, as compared to the IgD subtype patients with abnormal sFLC ratio, those with normal sFLC ratio had a numerically superior OS (42.56 months vs. 5.7 months, P = 0.057, Additional file 3: Figure S2). There was noted solely as a tendency, which may have been most likely due to the small cohort size.

High-risk cytogenetic abnormalities in MM patients with IgD subtype have been reported to range from 30 to 50%. In our study, 1q21 amplification was observed in 75% of patients with IgD subtype. It was reported that the overexpression of genes mapping to 1q21 could regulate the growth and resistance of MM to drugs, and result in increasing risk of early death of the patients [10]. Recent research has also found that the adverse effects due to 1q21 amplification on prognosis persisted even after removal of other identified high-risk cytogenetic changes, including p53 deletion, t(4;14), t(14;16), and t(14;20) [11]. Therefore, the association of IgD MM with a high rate of 1q21 amplification might contribute to poor outcomes. Perhaps it could also explain why patients with IgD subtype and non-IgD subtypes had similar response rates, but different duration of response.

Researchers have tried different ways to improve the prognosis of patients with IgD subtype all along. In 2005, Wechalekar et al. [5] suggested that the mean OS of IgD subtype patients could be prolonged after ASCT when compared with chemotherapy (5.1 years vs. 2 years, respectively, P = 0.090). In 2014, Zagouri et al. [12] reported a median OS of 51.5 months in 31 IgD subtype patients in Greece, which was the longest survival treated with chemotherapy reported until now. However, in Asia, the data seemed less consistent. In 2008 and 2010, two studies from Korea reported poor outcomes for the IgD subtype patients following ASCT or conventional chemotherapy, with the median OS of 12 and 18.5 months [4, 7]. In 2015, a report from China showed that the median OS and PFS of IgD subtype were 24 and 15.5 months, respectively and no difference in OS was found among the bortezomib-only group, the non-bortezomib group, and the bortezomib + ASCT group [8]. Here, our patients with IgD subtype showed similar median OS (22.9 months) and PFS (10 months) as to these studies from Asia. Though patients with non-IgD subtypes had a favourable median OS of 81.7 months in our study, in the era of novel agents, the survival of patients with IgD subtype still cannot be improved from the new drugs, unlike the non-IgD subtypes. Recently, a case report on a patient with IgD subtype who was refractory to at least 5 different chemotherapy regimens had shown very good partial response to daratumumab (anti-CD38 monoclonal antibody) [13]. We expect that additional agents with novel mechanism including histone deacetylation, target of surface receptors, and chimeric antigen receptor T Cell immunotherapy would improve the survival of IgD subtype patients.

In summary, the IgD subtype was found to be an independent adverse risk factor for prognosis. MM patients with IgD subtype presented with a more aggressive disease course and had shorter survival with chemotherapy as compared to the non-IgD subtypes, even in this era of novel agents. Considering the rarity of this subtype, international collaborative studies are suggested to confirm our findings and further elucidate the underlying mechanisms for developing potent therapeutic approaches.

Availability of data and materials

The dataset used or analyzed during the current study are available from the corresponding author on reasonable request.



autologous stem cell transplantation

AL amyloidosis:

amyloid light-chain amyloidosis


high β2 microglobulin


complete response


confidence interval


hazard ratio


immunoglobulin D multiple myeloma


immunoglobulin heavy chain gene


immunomodulatory drug


international staging system


lactate dehydrogenase


overall survival


progressive disease


progression-free survival


partial response


serum-free light chain


strict complete response


stable disease


very good partial response


  1. 1.

    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.

    CAS  Article  Google Scholar 

  2. 2.

    Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncology. 2013;27(8):798–803.

    PubMed  Google Scholar 

  3. 3.

    Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma: review of 133 cases. Arch Intern Med. 1975;135(1):87–93.

    CAS  Article  Google Scholar 

  4. 4.

    Kim MK, Suh C, Lee DH, Min C-K, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2010;22(2):411–6.

    Article  Google Scholar 

  5. 5.

    Wechalekar A, Amato D, Chen C, Stewart AK, Reece D. IgD multiple myeloma—a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol. 2005;84(2):115–7.

    Article  Google Scholar 

  6. 6.

    Francesco P, Teresa PM, Diana G, Velia B, Marco M, Valerio DS, et al. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. J Exp Clin Cancer Res. 2012;31(1):17.

    Article  Google Scholar 

  7. 7.

    Yong PC, Kim S, Ko OB, Koo JE, Lee D, Sang HP, et al. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci. 2008;23(5):819.

    Article  Google Scholar 

  8. 8.

    Wang GR, Sun WJ, Chen WM, Huang ZX, Zhang JJ, An N, et al. Immunoglobulin D multiple myeloma: disease profile, therapeutic response, and survival. Acta Haematol. 2016;136(3):140–6.

    CAS  Article  Google Scholar 

  9. 9.

    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.

    CAS  Article  Google Scholar 

  10. 10.

    Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995.

    CAS  Article  Google Scholar 

  11. 11.

    Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349–55.

    CAS  Article  Google Scholar 

  12. 12.

    Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, et al. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol. 2014;92(4):308–12.

    CAS  Article  Google Scholar 

  13. 13.

    Husnain M, Kurtin S, Barkett N, Riaz IB, Agarwal A. Refractory IgD multiple myeloma treated with daratumumab: a case report and literature review. Case Rep Oncol Med. 2017;2016(10):2490168.

    Google Scholar 

Download references


We would like to thank all the doctors and nurses of Jinling Hospital, and in particular many colleagues for referring and providing clinical data. We would like to thank all patients participated in this study and who attend our center.


Not applicable.

Author information




QZ and FL analyzed the data and prepared the paper. YPZ designed the research and checked the data. PS, XGZ, ZMA, XLW, and XG provided the clinical data and were responsible for the data interpretation. JGM, HQL, and JJS conformed the diagnosis and cytogenetics data and were responsible for reviewing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yongping Zhai.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Clinical Research Ethics Committee of Jinling Hospital, Nanjing, China. Written informed consent was waived by the ethics committee.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplementary information

Additional file 1: Table S1. Univariate analysis for PFS and OS of 216 patients with multiple myeloma.

Additional file 2: Figure S1. Kaplan–Meier overall survival curves of patients with multiple myeloma. a: Survival curves of patients stratified according to β2M, ≤ 5.5 mg/L vs. > 5.5 mg/L (P = 0.002); b: Survival of patients according to LDH, ≤ 250U/L vs. > 250U/L (P < 0.001); c: Survival of patients with and without extramedullary infiltration (P < 0.000); d: Survival of patients with and without ISS stage III (P = 0.028); e: Survival of patients with and without 13q deletion (P = 0.003); f: Survival of patients with and without 1q21 amplification (P < 0.000); g: Survival of patients with and without different IGH rearrangement [non-IGH rearrangement vs. t(4;14) vs. t(11;14) vs. t(14;16), P < 0.000]; h: Survival of patients with and without abnormal sFLC ratios (P = 0.035).

Additional file 3: Figure S2. Overall survival in IgD myeloma patients with and without abnormal sFLC ratio.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, Q., Li, F., Song, P. et al. Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience. Cancer Commun 39, 51 (2019).

Download citation